1,3,5-Tris(3,3,3-trifluoropropyl)methylcyclotrisiloxane

We are 1,3,5-Tris(3,3,3-trifluoropropyl)methylcyclotrisiloxane CAS:2374-14-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:1,3,5-Tris(3,3,3-trifluoropropyl)methylcyclotrisiloxane
CAS.NO:2374-14-3
Synonyms:1,3,5-Tris(3,3,3-trifluoropropyl)-1,3,5-trimethylcyclotrisiloxane; Fluorosilicone cyclic trimer; Tristrifluoropropylmethylcyclotrisiloxane; 
1,3,5-Tris[(3,3,3-trifluoropropyl)methyl]cyclotrisiloxane;
Molecular Formula:C12H21F9O3Si3
Molecular Weight:468.53500
 
Physical and Chemical Properties:
Density:1.24;
Melting point:35oC;
Boiling point:95oC;
Flash point:90oC;
Index of Refraction:1.38;
 
Specification:
Appearance:Translucent to white waxy solid
Purity(GC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It is used for manufacturing of fluorosilicone rubber (fluorinated silicone rubber, FSR), fluorosilicone fluid(fluorinated silicone fluid).

1,3,5-Tris(3,3,3-trifluoropropyl)methylcyclotrisiloxane


Related News: The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.3-BAP2NA-B CAS:944801-33-6 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.rac-1-(4-Fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile CAS:64169-67-1 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.42518-98-9 ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.

Related Products
Product Name
5-Chloro-2-fluoropyridine View Details
1-[pyrrolidin-1-ium-1-ylidene(pyrrolidin-1-yl)methoxy]pyrrolidine-2,5-dione,hexafluorophosphate View Details
N,N,N,N-Tetramethylchloroformamidinium Hexafluorophosphate View Details
2-Methoxy-4-[4-(4-Methylpiperazin-1-yl)piperidin-1-yl]aniline manufacturer 2,4-Difluoronitrobenzene manufacturer (R)-3-((tert-Butyldimethylsilyl)oxy)-5-methoxy-5-oxopentanoic acid manufacturer α-Bisabolol manufacturer BOC-ALANINE-1-HYDROXYSUCCINIMIDE ESTER manufacturer